Jme Group Inc

jme group, inc. is a privately held, biotechnology company founded on march 2014 in new jersey, u.s. the company embarked on a project to develop and commercialize a safer and affordable enzyme replacement therapy (ert) for metabolic and lysosomal storage diseases (a group of rare (orphan) diseases deficient in lysosomal enzymes) via oral administration (hence oral-ert) using plant-derived recombinant human enzymes or proteins plus natural non-gmo plant products for improvement of human and animal health. the first enzyme in the pipeline using this platform is a recombinant human lysosomal acid alpha-glucosidase (gaa) or acid maltase produced in tobacco seeds for the treatment of acid maltase deficiency (amd or pompe disease). ​